Provider Briefing: The Ongoing Carac Supply Challenge

If your patients have been reporting difficulty filling Carac (Fluorouracil 0.5% cream) prescriptions, you're hearing a widespread complaint. Carac has faced intermittent but persistent supply disruptions that continue into 2026, creating challenges for dermatology practices, primary care providers, and the patients who depend on this medication for actinic keratosis management.

This briefing covers the current state of Carac availability, the factors driving supply issues, prescribing implications, cost and access considerations, and practical tools to help you and your patients navigate the shortage.

Timeline: How We Got Here

Carac has experienced supply variability for several years. Key factors in the timeline include:

• Single-manufacturer dependency: Carac is produced exclusively by Bausch Health (formerly Valeant Pharmaceuticals). This single-source status has been the fundamental vulnerability in the supply chain.
• No generic entry at 0.5%: Despite generic Fluorouracil being widely available at 5% concentration, no manufacturer has brought a generic 0.5% formulation to market. This leaves Carac without competitive supply backup.
• Periodic production disruptions: Manufacturing slowdowns, raw material sourcing challenges, and distribution changes have contributed to gaps in availability over the past several years.
• Ongoing in 2026: As of early 2026, pharmacies in many regions continue to report inconsistent ability to source Carac through standard wholesale channels.

Prescribing Implications

The Carac shortage creates several practical challenges for prescribers:

Prescription Fulfillment Delays

Patients may present to your office reporting that their pharmacy cannot fill a Carac prescription. This can delay treatment initiation for actinic keratoses — a concern given that untreated AKs carry a risk of progression to squamous cell carcinoma.

Step Therapy and Prior Authorization

Many insurance plans already require step therapy (trial of generic Fluorouracil 5% before covering Carac) or prior authorization. Combined with supply issues, this creates a double barrier: patients may need Carac specifically because they didn't tolerate the 5% formulation, yet they still can't access it due to availability constraints.

Patient Frustration and Adherence

Extended searches for Carac can erode patient trust and reduce treatment adherence. Patients who struggle to fill their prescription may delay or abandon treatment altogether. Proactive communication about availability challenges and backup plans can help maintain the therapeutic relationship.

Documentation Considerations

When prior authorization is required, thorough documentation of medical necessity is essential. Key points to include:

• Prior trial and failure or intolerance of Fluorouracil 5%
• Specific clinical rationale for the 0.5% concentration (e.g., treatment of facial AKs where tolerability is critical)
• Location and extent of actinic keratoses
• Patient history of skin cancer or high-risk features

Current Availability Picture

Carac availability in 2026 is best described as inconsistent and regionally variable. Key observations:

• Large chain pharmacies (CVS, Walgreens, Rite Aid) frequently report Carac as unavailable or not regularly stocked.
• Independent pharmacies with access to multiple wholesalers sometimes have better success sourcing it.
• Specialty pharmacies focused on dermatology may maintain more reliable inventory.
• Mail-order options through specialty pharmacy channels may offer an alternative when local supply is exhausted.

Availability can shift on a weekly basis, making real-time tracking tools essential for both providers and patients.

Cost and Access Considerations

Even when Carac is available, cost remains a significant barrier:

• Cash price: $800 to $1,500+ for a 30g tube
• Insurance coverage: Variable. Many plans tier Carac as a non-preferred brand or specialty medication, resulting in high copays ($50-$200+). Prior authorization is common.
• Generic Fluorouracil 5%: $30 to $150 without insurance — dramatically more affordable and widely available
• Patient assistance: Bausch Health offers a patient assistance program for uninsured or underinsured patients. Manufacturer savings cards may reduce copays for commercially insured patients.

For patients facing cost barriers, a detailed guide is available at how to save money on Carac.

Tools and Resources for Providers

Several resources can help your practice manage the Carac supply challenge:

Medfinder for Providers

Medfinder offers real-time pharmacy availability data that you and your staff can use to direct patients to pharmacies that currently have Carac in stock. This is significantly more efficient than having patients call multiple pharmacies on their own.

Alternative Medication Options

When Carac is unavailable, consider these evidence-based alternatives:

• Generic Fluorouracil 5% cream: Same active ingredient, higher concentration. Most widely available and affordable option. Consider for patients who can tolerate increased local reactions.
• Imiquimod 5% (Aldara) or 3.75% (Zyclara): Immune-mediated mechanism. Useful for patients who cannot tolerate any Fluorouracil formulation.
• Diclofenac 3% gel (Solaraze): Better tolerated but requires 60-90 days of treatment. Appropriate for milder AKs.
• Tirbanibulin 1% (Klisyri): Newest approved option. Only 5 days of treatment. Increasingly covered by insurance.
• Cryotherapy or photodynamic therapy: Procedural alternatives for patients who prefer or require in-office treatment.

Prescription Transfer and Mail-Order

If a patient locates Carac at a distant pharmacy via Medfinder, your office can facilitate a prescription transfer. Many specialty pharmacies also offer mail-order delivery, which can expand access beyond the patient's immediate geographic area.

Looking Ahead

The fundamental issue — single-source manufacturing with no generic equivalent at 0.5% — is unlikely to change in the near term. Providers should plan for continued intermittent supply disruptions and consider:

• Having a standing alternative recommendation ready for patients who can't access Carac
• Incorporating real-time availability tools like Medfinder into clinical workflows
• Proactively discussing backup plans with patients at the time of prescribing
• Documenting step therapy failures thoroughly to support future prior authorizations

Final Thoughts

The Carac shortage is a manageable challenge, but it requires proactive planning. By staying informed about supply trends, maintaining familiarity with alternative treatments, and leveraging tools like Medfinder for providers, you can continue to deliver effective actinic keratosis management even when Carac is difficult to source.

For patient-facing resources you can share, see our posts on why Carac is hard to find and alternatives to Carac.